# Cannabinoids and Dementia: New Meta-Analysis Finds No Clear Benefit > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-dementia-symptoms-meta-analysis/ > **Published:** 2026-09-09T09:44:34-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:06-04:00 > **Clinical Summary:** cannabinoids dementia meta-analysis: A new systematic review and meta-analysis of nine randomized trials involving 334 participants found no clear improvemen... --- CED Clinical Relevance #88 High Clinical Relevance A same-day systematic review and meta-analysis of nine randomized trials directly addresses efficacy and safety in dementia, with null pooled outcomes and a clinically important somnolence signal. Clinical Insight | CED Clinic A new systematic review and meta-analysis of nine randomized trials involving 334 participants found no clear improvement in agitation, broader neuropsychiatric symptoms, or cognition with cannabinoid-based interventions in dementia. Overall adverse events were similar to placebo, but somnolence was more frequent. The findings argue for caution when individual trial signals appear more favorable than the pooled evidence. The most clinically useful reading weighs symptom scales against alertness, mobility, and everyday function in each patient’s care setting. DementiaCannabinoidsMeta-AnalysisAgitationSafety AudiencePatients, caregivers, clinicians, and cannabis-science readers interested in agitation, neuropsychiatric symptoms, and cognition in Alzheimer’s disease and dementia Primary Topiccannabinoid-based interventions for behavioral and cognitive symptoms in dementia Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42704497/) A new systematic review and meta-analysis of nine randomized trials involving 334 participants found no clear improvement in agitation, broader neuropsychiatric symptoms, or cognition with cannabinoid-based interventions in dementia. Overall adverse events were similar to placebo, but somnolence was more frequent. The findings argue for caution when individual trial signals appear more favorable than the pooled evidence. What This Study Teaches Us The pooled randomized evidence did not show statistically clear benefit on the Cohen-Mansfield Agitation Inventory, total or agitation-specific Neuropsychiatric Inventory measures, or Mini-Mental State Examination scores. Somnolence occurred more often with cannabinoids, with a reported risk ratio of 2.03. Why This Matters [Behavioral symptoms](https://cedclinic.com/cbd-gummies-for-dementia-evidence-cognitive-behavioral-support/) in dementia can be deeply distressing, and current treatments are imperfect. A careful synthesis matters because symptom relief must be weighed against sedation, falls, function, caregiver burden, and the uncertainty created by small heterogeneous trials. Study SnapshotStudy TypeSystematic review and meta-analysis of randomized controlled trialsPopulationPeople with Alzheimer’s disease or dementiaTrials IncludedNine randomized trialsParticipants334 total participantsPrimary OutcomesCMAI agitation and NPI-NH neuropsychiatric symptomsCMAI ResultSMD -0.58, 95% CI -1.71 to 0.55; I² 84%NPI-NH TotalSMD -0.02, 95% CI -1.00 to 0.96; I² 67%NPI-NH AgitationSMD -0.44, 95% CI -1.45 to 0.57; I² 48%CognitionMMSE SMD 0.86, 95% CI -16.33 to 18.06; I² 96%SomnolenceRR 2.03, 95% CI 1.29 to 3.20CertaintyModerate for behavioral outcomes and low for cognitionPublishedSeptember 7, 2026PMID42704497DOI10.1007/s10072-026-09347-z Clinical Bottom Line Across nine randomized trials, cannabinoid-based interventions did not show clear pooled benefit for agitation, neuropsychiatric symptoms, or cognition in dementia, and somnolence was more frequent than with placebo. The Pooled Behavioral Outcomes Were Not Clearly Improved The meta-analysis found no statistically clear improvement on the Cohen-Mansfield Agitation Inventory, the total Neuropsychiatric Inventory-Nursing Home score, or the agitation component of that inventory. Bayesian estimates were also reported near zero, and leave-one-out analyses did not change the overall conclusion even when influential trials affected heterogeneity. Cognition Also Remained Uncertain The pooled Mini-Mental State Examination estimate was highly imprecise, with a very wide confidence interval and substantial heterogeneity. The authors rated certainty as low for cognition, so the evidence does not support a claim that cannabinoids preserve or improve cognitive function in dementia. Somnolence Is the Clearest Safety Signal Overall adverse-event frequency was similar to placebo, but somnolence was more frequent with cannabinoid-based interventions, with a risk ratio of 2.03 and a 95% confidence interval from 1.29 to 3.20. In dementia care, sleepiness can affect mobility, falls, alertness, eating, communication, and caregiver workload. It deserves specific monitoring rather than being treated as a minor side effect. A Larger Synthesis Can Change the Clinical Reading Earlier individual trials and smaller syntheses have reported favorable agitation signals. This review pooled nine randomized trials and did not find a clear effect across its main behavioral outcomes. That difference is clinically useful. It shows why a promising study should be interpreted within the full evidence base, especially when interventions, participants, and outcome measures vary. How Strong Is This Evidence? The review centers randomized trials, reports both frequentist and Bayesian analyses, evaluates risk of bias with RoB 2, and grades certainty with GRADE. It includes 334 participants across nine trials and addresses behavioral, cognitive, and safety outcomes. Where This Paper Deserves Skepticism The abstract reports substantial heterogeneity for several outcomes, including I² values of 84 percent for CMAI, 67 percent for total NPI-NH, and 96 percent for MMSE. The full article was not openly accessible, so this report does not infer unreported formulation, dose, duration, or trial-level explanations. What This Paper Does Not Show The review does not prove that every cannabinoid, formulation, dose, or carefully selected patient will have the same response. It also does not establish a preferred alternative treatment. It shows that the pooled randomized evidence did not demonstrate clear benefit on the prespecified outcomes and that somnolence was increased. How This Fits With the Broader Clinical Conversation Dementia-related agitation has many possible contributors, including pain, infection, medication effects, unmet needs, environmental stress, sleep disruption, and progression of neurologic disease. A cannabinoid discussion should therefore sit inside a broader clinical assessment. Pooled null findings do not erase every individual observation, but they lower confidence that cannabinoids reliably improve these outcomes across patients. Dr. Caplan’s Take *I would use this review to reset expectations. Cannabinoids may still be discussed in selected situations, but the best current pooled evidence does not support presenting them as a reliably effective treatment for dementia-related agitation or cognitive symptoms.* *The somnolence signal is especially important. In older adults with dementia, sedation can trade one problem for another, so any trial of therapy requires explicit goals, close observation, and a willingness to stop when function or safety worsens.* What a Careful Reader Should Take Away Nine randomized trials did not show clear pooled benefit for behavioral or cognitive symptoms in dementia, while somnolence was more frequent with cannabinoids. Evidence Interpretation Guide Table of Contents - [How to Interpret This Cannabinoid-Based Interventions For Behavioral And Cognitive Symptoms In Dementia Evidence Without Overstating It](#How_to_Interpret_This_Cannabinoid-Based_Interventions_For_Behavioral_And_Cognitive_Symptoms_In_Dementia_Evidence_Without_Overstating_It)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [Eight Ways to Read the Dementia Evidence](#Eight_Ways_to_Read_the_Dementia_Evidence)[Promising Stories Are Not the Same as Reliable Benefit](#Promising_Stories_Are_Not_the_Same_as_Reliable_Benefit) - [Define the Target Before Considering Exposure](#Define_the_Target_Before_Considering_Exposure) - [Heterogeneity Limits a Simple Average](#Heterogeneity_Limits_a_Simple_Average) - [Somnolence Can Be a Functional Harm](#Somnolence_Can_Be_a_Functional_Harm) - [Observation Quality Matters Between Visits](#Observation_Quality_Matters_Between_Visits) - [New Pooled Evidence Can Reverse the Headline](#New_Pooled_Evidence_Can_Reverse_the_Headline) - [Calm Behavior Is Not the Only Goal](#Calm_Behavior_Is_Not_the_Only_Goal) - [Trials Need Product-Specific and Functional Answers](#Trials_Need_Product-Specific_and_Functional_Answers) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Cannabinoid-Based Interventions For Behavioral And Cognitive Symptoms In Dementia Evidence Without Overstating It A useful evidence report should let the signal breathe without inflating it. The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support. ### A Four-Step Reading Frame **Evidence type**Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol. **Population**Ask whether the studied population matches the patient or clinical scenario involving agitation, neuropsychiatric symptoms, and cognition in Alzheimer’s disease and dementia. **Outcome meaning**Look at what actually changed, how it was measured, and whether the change would matter in daily life. **Safety and uncertainty**Read limitations and adverse effects as part of the result, not as a footnote. The Research Question What does the current evidence suggest about cannabinoid-based interventions for behavioral and cognitive symptoms in dementia? The Patient Question Does this mean I should use cannabinoids for agitation, neuropsychiatric symptoms, and cognition in Alzheimer’s disease and dementia? The Bottom Line The evidence can inform a careful conversation, but it does not replace individualized clinical care. CED Perspective Lens ## Eight Ways to Read the Dementia Evidence Clinical, methodological, safety, caregiver, and ethics perspectives Lens OverviewEach viewpoint stays within the peer-reviewed abstract and distinguishes pooled evidence from individual treatment observations. #### Promising Stories Are Not the Same as Reliable Benefit Families may encounter individual reports suggesting that THC, CBD, or combined products reduce agitation in dementia. This review provides a broader view: across nine randomized trials, the pooled results did not show clear improvement in agitation, wider neuropsychiatric symptoms, or cognition. That does not invalidate every personal observation, but it changes the level of confidence. A treatment discussion should begin with the symptom being targeted, the desired functional change, and the risks that matter most for that person. Sleepiness, mobility, falls, appetite, communication, and alertness deserve explicit attention. Lens takeawayUse measurable goals and safety observations instead of relying on generalized treatment promises. #### Define the Target Before Considering Exposure Agitation is not a single diagnosis. Pain, delirium, infection, medication burden, sleep disruption, sensory impairment, environmental stress, and unmet needs can all contribute. A cannabinoid decision should follow a structured assessment of reversible causes and nonpharmacologic options. If cannabinoids are nevertheless considered, the pooled null findings should shape consent and follow-up. Document the target behavior, baseline frequency and severity, caregiver priorities, sedation risk, and a stopping rule. The abstract does not identify a formulation or dose with dependable benefit, so product-specific certainty would exceed the available evidence. Lens takeawayStart with cause-finding, then use explicit targets and stopping rules for any trial. #### Heterogeneity Limits a Simple Average The review reports substantial heterogeneity for CMAI, total NPI-NH, and MMSE outcomes. That means the trial results varied more than a single pooled estimate can fully explain, even though none of the main confidence intervals established a clear benefit. The accessible abstract does not provide enough detail to attribute that variation to a particular product, dose, duration, population, or trial method. The correct response is not to invent a subgroup explanation. It is to treat the average as uncertain and to seek full trial-level evidence before claiming that one approach works better. Lens takeawayHigh heterogeneity calls for restraint, not selective confidence in a favored formulation. #### Somnolence Can Be a Functional Harm Somnolence was more frequent with cannabinoids than placebo, with a reported risk ratio of 2.03. In a younger healthy population, sleepiness may be temporary inconvenience. In dementia care, it can interact with gait instability, frailty, swallowing, daytime engagement, and other sedating medicines. Overall adverse events were similar between groups, but that summary should not dilute the specific signal. Clinicians and caregivers need to monitor alertness and function, not only whether agitation appears quieter. Reduced visible behavior accompanied by reduced wakefulness is not automatically a meaningful therapeutic gain. Lens takeawayJudge benefit alongside alertness, mobility, participation, and other patient-centered safety outcomes. #### Observation Quality Matters Between Visits Caregivers often see changes that a brief office visit cannot capture. A short daily record of agitation episodes, sleepiness, falls, appetite, nighttime sleep, and participation can make a medication review more accurate and less dependent on memory. The review does not identify a reliable average benefit, so careful observation becomes even more important when an individual treatment trial occurs. Caregivers should know whom to contact, which changes require urgent attention, and when the prescriber plans to reassess. The burden of monitoring should also be acknowledged directly. Lens takeawaySimple daily tracking can distinguish meaningful improvement from sedation or ordinary fluctuation. #### New Pooled Evidence Can Reverse the Headline Earlier CED coverage discussed a smaller meta-analysis that reported lower agitation scores while emphasizing limited trials and somnolence. The new synthesis includes nine randomized trials and reports no clear benefit across agitation, total neuropsychiatric symptoms, or cognition. The two summaries should not be blended into a vague middle. The newer review contributes additional randomized evidence and a different pooled conclusion. That makes it a substantive update, not a repeat. Readers should compare included trials, methods, and outcome definitions when the full paper becomes accessible. Lens takeawayTreat the newer null synthesis as a meaningful update to earlier favorable signals. #### Calm Behavior Is Not the Only Goal Dementia care must protect comfort, dignity, communication, and participation. An intervention that reduces outward agitation by increasing sleepiness may not deliver the outcome the patient or family actually values, even when staff perceive the environment as calmer. Shared decisions should therefore specify whose goal is being pursued and how benefit will be recognized. The abstract supports caution about somnolence but does not report every patient-centered outcome. That gap should remain visible when discussing treatment, especially for people who cannot easily describe adverse effects themselves. Lens takeawayCenter comfort and function, not merely the reduction of behavior visible to others. #### Trials Need Product-Specific and Functional Answers The pooled findings do not identify a dependable behavioral or cognitive benefit, and the abstract reports important heterogeneity. Future trials should make formulation, cannabinoid ratio, dose, treatment duration, baseline syndrome, and concomitant medicines easy to compare across studies. They should also measure outcomes that matter beyond symptom scales, including alertness, falls, sleep, caregiver burden, quality of life, and treatment discontinuation. The current abstract does not settle whether a particular subgroup or product performs differently. Those questions require adequately powered, prospectively defined comparisons rather than post hoc assumptions. Lens takeawayFuture evidence should connect product-specific exposure to both symptoms and everyday function. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabinoids+and+Dementia%3A+New+Meta-Analysis+Finds+No+Clear+Benefit&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-dementia-symptoms-meta-analysis%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-dementia-symptoms-meta-analysis%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabinoids+and+Dementia%3A+New+Meta-Analysis+Finds+No+Clear+Benefit%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-dementia-symptoms-meta-analysis%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Efficacy and safety of cannabinoid-based interventions for behavioral and cognitive symptoms in dementia: systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42704497/) Related Reading at CED ClinicContinue exploring the evidence[Cannabinoids for Alzheimer’s Agitation: What a New Meta-Analysis Adds](https://cedclinic.com/cannabinoids-alzheimers-agitation-meta-analysis-full-report/) Earlier CED coverage of a smaller synthesis that reported an agitation signal and highlighted sedation risk. [Compare the earlier synthesis](https://cedclinic.com/cannabinoids-alzheimers-agitation-meta-analysis-full-report/)[THC and Alzheimer’s Agitation](https://cedclinic.com/thc-for-alzheimers-agitation-dronabinol-trial/) Trial-focused context on dronabinol and agitation, useful for separating individual-study signals from pooled evidence. [Review the trial context](https://cedclinic.com/thc-for-alzheimers-agitation-dronabinol-trial/)[THC/CBD Oil for Dementia Agitation: What the MedCanDem Trial Found](https://cedclinic.com/thc-cbd-oil-dementia-agitation-crossover-rct/) Recent randomized crossover evidence on a THC/CBD formulation in dementia-related agitation. [Read the randomized trial](https://cedclinic.com/thc-cbd-oil-dementia-agitation-crossover-rct/) Similar Studies on CEDClinic.comEarlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [CBD and CBG Restored Memory in Animal Model of Iron-Related](https://cedclinic.com/cbd-cbg-neuroprotective-effects-iron-related-brain-damage/) Cbd and cbg neuroprotective effects iron-related brain damage: Emerging research shows that CBD and CBG exhibit neuroprotective effects in animal models of iron-related brain damage. These cannabinoids restored memory f… Covers a closely related topic; this CED post is older by about 10 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cbd-cbg-neuroprotective-effects-iron-related-brain-damage/) Related digest item [LiBBY Trial: THC/CBD Eases End-of-Life Dementia Agitation](https://cedclinic.com/libby-trial-thc-cbd-eases-end-of-life-dementia-agitation/) ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. NeurologyResearchTHCCBDAgingMental HealthSafety Why This Matters This trial provides cli… Covers a closely related topic; this CED post is older by about 40 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/libby-trial-thc-cbd-eases-end-of-life-dementia-agitation/) Related digest item [New Studies Find Cannabis Reduces Alzheimer’s-Induced Agitation](https://cedclinic.com/new-studies-find-cannabis-reduces-alzheimers-induced-agitation/) ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyAgingTHCCBDResearchMental HealthSafety Why This Matters Clinicians managing behavior… Covers a closely related topic; this CED post is older by about 44 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/new-studies-find-cannabis-reduces-alzheimers-induced-agitation/) Related digest item [Medicinal cannabis approved in landmark court ruling for elderly suffering dementia in aged care](https://cedclinic.com/medicinal-cannabis-approved-in-landmark-court-ruling-for-elderly-suffering-dementia-in-aged-care/) ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AgingNeurologyCBDTHCPolicyMental HealthResearch Why This Matters Clinicians now have leg… Covers a closely related topic; this CED post is older by about 46 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/medicinal-cannabis-approved-in-landmark-court-ruling-for-elderly-suffering-dementia-in-aged-care/) Related digest item [THC-CBD Combination Reduces Agitation in Advanced Dementia](https://cedclinic.com/thc-cbd-combination-reduces-agitation-in-advanced-dementia/) ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchCBDTHCAgingMental HealthSafety Why This Matters Clinicians treating advanced… Covers a closely related topic; this CED post is older by about 49 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/thc-cbd-combination-reduces-agitation-in-advanced-dementia/) Related digest item [THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or …](https://cedclinic.com/thc-and-cbd-from-marijuana-reduces-agitation-in-9-out-of-10-people-with-alzheimers-or/) ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyTHCCBDAgingMental HealthSafety Why This Matters Clinicians treating Alzheime… Covers a closely related topic; this CED post is older by about 49 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/thc-and-cbd-from-marijuana-reduces-agitation-in-9-out-of-10-people-with-alzheimers-or/) Related digest item [Last Week in Weed July 14-20, 2026: Cannabis Shows Promise for Agitation in Dementia](https://cedclinic.com/last-week-in-weed-july-14-20-2026-cannabis-shows-promise-for-agitation-in-dementia/) ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyAgingResearchDosingSafetyPolicyMental Health Why This Matters Clinicians treating de… Covers a closely related topic; this CED post is older by about 49 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/last-week-in-weed-july-14-20-2026-cannabis-shows-promise-for-agitation-in-dementia/) Related digest item [Can weed help dementia patients? Study finds surprising upsides](https://cedclinic.com/can-weed-help-dementia-patients-study-finds-surprising-upsides/) ✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchAgingCBDTHCMental HealthSafety Why This Matters Clinicians treating late-sta… Covers a closely related topic; this CED post is older by about 49 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/can-weed-help-dementia-patients-study-finds-surprising-upsides/) Related digest item [Can weed help dementia patients? Study finds surprising upsides](https://cedclinic.com/can-weed-help-dementia-patients-study-finds-surprising-upsides/) ✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchTHCCBDAgingMental HealthSafety Why This Matters Clinicians managing dementia… Covers a closely related topic; this CED post is older by about 50 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/can-weed-help-dementia-patients-study-finds-surprising-upsides/) Related digest item [Could cannabis be used to treat Alzheimer’s?](https://cedclinic.com/could-cannabis-be-used-to-treat-alzheimers/) ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchAgingTHCCBDMental HealthSafety Why This Matters Clinicians treating Alzheime… Covers a closely related topic; this CED post is older by about 52 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/could-cannabis-be-used-to-treat-alzheimers/) ## Frequently Asked Questions What did the new dementia meta-analysis examine? It examined randomized trials of cannabinoid-based interventions for agitation, broader neuropsychiatric symptoms, cognition, and adverse events in Alzheimer’s disease or dementia. How many trials and participants were included? Nine randomized trials involving 334 participants met the review criteria. Did cannabinoids clearly improve agitation? No. The pooled CMAI and NPI-NH agitation estimates did not show statistically clear improvement. Did cannabinoids improve cognition? No clear cognitive benefit was shown. The MMSE estimate was highly imprecise, and certainty for cognition was rated low. What was the main safety finding? Somnolence was more frequent with cannabinoids, with a risk ratio of 2.03 and a 95% confidence interval from 1.29 to 3.20. Were overall adverse events increased? The abstract reports that overall adverse events were similar to placebo, while somnolence was specifically increased. Why do these results differ from some earlier reports? Individual trials and smaller syntheses can produce different estimates. This review pooled nine randomized trials and reported substantial heterogeneity for several outcomes. Does this prove that no cannabinoid can ever help an individual? No. It shows that pooled randomized evidence did not demonstrate reliable benefit across the studied outcomes. It does not establish that every product, dose, or patient response is identical. What should clinicians monitor if cannabinoids are considered? Clinicians should define the target symptom and monitor alertness, mobility, falls, participation, sleep, other sedating medicines, and whether meaningful function improves. Was the full article available for this review? No open full text was found through PubMed Central or Unpaywall. Study-specific claims are therefore confined to the peer-reviewed abstract and registered metadata. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).